Overview
Share price change
24h
Current
Min
238.59
Max
243.9
Income | -100M 193M |
|---|---|
Sales | 139M 1.2B |
P/E Sector Avg | 16.893 56.597 |
EPS | 4.89 |
Profit margin | 15.956 |
Employees | 2,890 |
EBITDA | -126M 418M |
Next Earnings | 4 Nov 2026 |
|---|
Market Cap | 138M 16B |
|---|---|
Previous open | 239.98 |
Previous close | 239.85 |
News Sentiment
By Acuity
50%
50%
146 / 339 Healthcare
Jazz Pharmaceuticals PLC Chart
Past performance is not a reliable indicator of future results.
Related News
8 Sept 2026, 20:03 UTC
Jazz Pharmaceuticals PLC is declining amid broader pharmaceuticals sector weakness, breaking a recent trend of higher daily closes since Friday.
Read
4 Sept 2026, 19:36 UTC
Jazz Pharmaceuticals PLC shares are lower today amid rising Treasury yields and strong labor market data, reflecting broader market trends.
Read
3 Sept 2026, 21:21 UTC
Jazz Pharmaceuticals PLC shares are lower in after-market hours, reflecting ongoing pressure despite broader market strength and decreasing rate hike expectations.
Read
2 Sept 2026, 19:46 UTC
Jazz Pharmaceuticals PLC shares are higher today, despite an earlier pullback. Broader market conditions include rising U.S. Treasury yields amid inflation concerns.
Read
1 Sept 2026, 19:54 UTC
Jazz Pharmaceuticals shares are lower despite positive Phase 3 trial results for Ziihera, influenced by tightening monetary policy expectations and rising Treasury yields.
Read
31 Aug 2026, 23:41 UTC
Jazz Pharmaceuticals PLC reported positive results from the HERIZON-GEA-01 trial for Ziihera, leading shares higher in after-hours trading.
Read
28 Aug 2026, 20:02 UTC
Jazz Pharmaceuticals PLC shares are lower today, reversing a trend of higher closes. Broader market pressures include rising U.S. Treasury yields amid inflation concerns.
Read
26 Aug 2026, 20:08 UTC
Jazz Pharmaceuticals PLC shares are lower following a $1 billion note offering and potential $225 million buyback, despite positive FDA approvals and target raises from analysts.
Read
25 Aug 2026, 20:07 UTC
Jazz Pharmaceuticals rises on FDA approval of Ziihera for treating advanced HER2-positive gastroesophageal cancer. Bank of America sets price target at $307.
Read
24 Aug 2026, 19:26 UTC
Jazz Pharmaceuticals shares are lower amid broader market sentiment influenced by geopolitical tensions. Ziihera's potential in the HER2+ market presents a growth opportunity.
Read
22 Aug 2026, 00:02 UTC
Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline since Friday's close, despite broader gains in major U.S. stocks.
Read
21 Aug 2026, 20:06 UTC
Jazz Pharmaceuticals PLC shares are higher during Friday's session, reflecting strong upward momentum since Thursday's close, despite a recent pullback from session highs.
Read
20 Aug 2026, 19:56 UTC
Jazz Pharmaceuticals PLC shares are lower amid a broader market decline following disappointing sales growth and guidance from Walmart. They remain below their 20-day moving average.
Read
19 Aug 2026, 22:36 UTC
Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline from regular trading, despite a broader recovery in equities.
Read
18 Aug 2026, 20:03 UTC
Jazz Pharmaceuticals shares are trading higher, reflecting strength in the pharmaceuticals sector, despite a slight pullback from earlier session gains.
Read
17 Aug 2026, 23:31 UTC
Jazz Pharmaceuticals PLC shares declined during after-market hours, reflecting broader market pressures from rising crude oil prices amid escalating U.S.-Iran tensions.
Read
12 Aug 2026, 19:46 UTC
Jazz Pharmaceuticals shares are higher after Q2 revenue rose 16% to $1.21 billion, exceeding expectations. The company raised its full-year guidance to $4.68 billion.
Read
11 Aug 2026, 22:46 UTC
Jazz Pharmaceuticals PLC shares advanced in after-market trading, diverging from broader market trends that closed lower amid rising crude oil prices.
Read
10 Aug 2026, 19:56 UTC
Jazz Pharmaceuticals PLC to acquire Actio Biosciences for $820 million, enhancing its rare epilepsy portfolio. Shares are higher despite earlier session pullback.
Read
7 Aug 2026, 19:36 UTC
Jazz Pharmaceuticals shares are higher today, reflecting broader market gains amid expectations the Federal Reserve may pause interest rate hikes.
Read
6 Aug 2026, 19:21 UTC
Jazz Pharmaceuticals PLC shares are lower today, despite earlier gains. Mixed economic signals contribute to cautious sentiment ahead of the non-farm payrolls report.
Read
5 Aug 2026, 19:36 UTC
Shares of Jazz Pharmaceuticals PLC are lower today, despite earlier gains. The company raised its full-year revenue guidance, driven by strong performance from Xywav.
Read
4 Aug 2026, 20:04 UTC
Jazz Pharmaceuticals PLC shares rise as analysts upgrade price targets, following strong Q2 results that beat revenue estimates and boosted 2026 sales guidance.
Read
3 Aug 2026, 23:02 UTC
Jazz Pharmaceuticals reported Q2 revenues of $1.208 billion, exceeding expectations. Shares advanced in after-market trading following the raised full-year guidance.
Read
31 Jul 2026, 23:21 UTC
Jazz Pharmaceuticals PLC shares are lower in after-market trading, pulled back from earlier session highs amid broader market declines, particularly in major tech stocks.
Read
30 Jul 2026, 19:59 UTC
Jazz Pharmaceuticals shares are higher, reflecting broader market recovery amid significant gains in the technology sector. The stock is near the upper end of its one-month range.
Read
29 Jul 2026, 18:26 UTC
Jazz Pharmaceuticals PLC is trading higher during Wednesday's session, with fluctuations within a routine range and positioned above its 20-day moving average.
Read
28 Jul 2026, 23:46 UTC
Jazz Pharmaceuticals PLC shares are higher in after-market trading, recovering from an early low and remaining above the 20-day moving average.
Read
27 Jul 2026, 19:37 UTC
Jazz Pharmaceuticals PLC is trading higher, recently reaching a new 52-week high amid increased investor interest and significant average volume exceeding $50 million.
Read
24 Jul 2026, 20:07 UTC
Jazz Pharmaceuticals PLC shares are lower today amid broader market dynamics influenced by recent oil price volatility, despite remaining above its 20-day moving average.
Read
Peer Comparison
Price change
Jazz Pharmaceuticals PLC Forecast
Rating Consensus
By TipRanks
Strong Buy
16 ratings
16
Buy
0
Hold
0
Sell
Based on 16 analysts giving stock ratings to Jazz Pharmaceuticals PLC - Dist in the past 3 months.
Sentiment
By Acuity
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$